Amgen (NASDAQ:AMGN) executives outlined the company’s oncology research and development priorities and provided updates on ...

Amgen (AMGN) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of ...

Amgen is running a number of studies of its obesity drug, MariTide.

When measured against the market's most prolific capital-return leaders, Amgen’s ability to maintain this level of ...

On February 17, 2026, Amgen Inc. issued and sold a total of $4 billion in senior unsecured notes across four tranches maturing between 2031 and 2056, carrying coupons ranging from 4.200% to 5.650%.

Executives at Amgen (NASDAQ:AMGN) outlined several upcoming clinical milestones and recent data updates across its ...

But Amgen’s true success stems from putting people first. By creating an environment where innovation, inclusion and ...

Amgen is among a crowded field of drugmakers racing to develop the next blockbuster weight loss drug — but it's taking an entirely different approach than its rivals. The biotech company is testing a ...

Amgen led four borrowers that raised $6.4bn on Monday. It was joined by Howmet Aerospace (Baa1/A-), which came to the market ...

Compared to the aggregate P/E ratio of the 83.91 in the Biotechnology industry, Amgen Inc. has a lower P/E ratio of 26.69. Shareholders might be inclined to think that the stock might perform worse ...

Agency raised questions about avacopan's pivotal trial data and concerns of hepatotoxicity ...

(Corrects paragraph 5 in February 5 story to say 2025 Prolia sales were $4.4 billion, not $1.05 billion) Feb 5 (Reuters) - CVS Health said on Thursday it would swap out Amgen and Eli Lilly's bone ...